Synapse
⌘+K
Sign In
Sign Up for Free
Synapse
Sign In
Sign Up for Free
Home
Communities
Explore
More
Language
English
English
Atuka (Canada)
h-index: 16
Total citations: 823
Total papers: 34
Homepage:
https://atuka.com/
Recent papers from Atuka (Canada)
A small molecule reduces both parkinsonism and l -dopa–induced dyskinesia in animal models of Parkinson’s disease
Science Translational Medicine · 2026
Roles of astrocytic Connexin 43 gap junctional deficit in alpha-synucleinopathy and inflammation relevant to Parkinson’s
Experimental Neurology · 2026
Low β predicts motor output and cell degeneration in the A53T Parkinson’s disease rat model
Brain · 2025
Using artificial intelligence to identify drugs for repurposing to treat l-DOPA-induced dyskinesia
Neuropharmacology · 2024
Brain-to-gut trafficking of alpha-synuclein by CD11c+ cells in a mouse model of Parkinson’s disease
Nature Communications · 2023
Inflammasome inhibition protects dopaminergic neurons from α-synuclein pathology in a model of progressive Parkinson’s disease
Journal of Neuroinflammation · 2023
Alterations in the LRRK2-Rab pathway in urinary extracellular vesicles as Parkinson’s disease and pharmacodynamic biomarkers
npj Parkinson s Disease · 2023
Expansion of regulatory T cells by CD28 superagonistic antibodies attenuates neurodegeneration in A53T-α-synuclein Parkinson’s disease mice
Journal of Neuroinflammation · 2022
Toward in vivo proof of binding of 18F-labeled inhibitor [18F]TRACK to peripheral tropomyosin receptor kinases
EJNMMI Research · 2022
Temporal, spatial and molecular pattern of dopaminergic neurodegeneration in the AAV-A53T α-synuclein rat model of Parkinson’s disease
Behavioural Brain Research · 2022
P2B001 (Extended Release Pramipexole and Rasagiline): A New Treatment Option in Development for Parkinson’s Disease
Advances in Therapy · 2022
α-Synuclein–induced Kv4 channelopathy in mouse vagal motoneurons drives nonmotor parkinsonian symptoms
Science Advances · 2021
Exosome markers of LRRK2 kinase inhibition
npj Parkinson s Disease · 2020
Pharmacodynamic Markers of LRRK2 Inhibition in Biofluids
2020
NYX‐458 Improves Cognitive Performance in a Primate Parkinson's Disease Model
Movement Disorders · 2020
Viewpoint: Developing drugs for levodopa‐induced dyskinesia in PD: Lessons learnt, what does the future hold?
European Journal of Neuroscience · 2018
Towards a Non-Human Primate Model of Alpha-Synucleinopathy for Development of Therapeutics for Parkinson’s Disease: Optimization of AAV1/2 Delivery Parameters to Drive Sustained Expression of Alpha Synuclein and Dopaminergic Degeneration in Macaque
PLoS ONE · 2016
Use of catechol‐O‐methyltransferase inhibition to minimize L‐3,4‐dihydroxyphenylalanine‐induced dyskinesia in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐lesioned macaque
European Journal of Neuroscience · 2013
The selective mu‐opioid receptor antagonist adl5510 reduces levodopa‐induced dyskinesia without affecting antiparkinsonian action in mptp‐lesioned macaque model of Parkinson's disease
Movement Disorders · 2011
Advances in the delivery of treatments for Parkinson’s disease
Expert Opinion on Drug Delivery · 2005